HTG Molecular Appoints Dr. Maureen T. Cronin as Chief Scientific Officer and Senior Vice President
“HTG is incredibly honored to have Maureen join our company as she brings extensive experience in developing high-value precision diagnostics,” said TJ Johnson, Chief Executive Officer of HTG. “Maureen’s technology background, including most recent senior roles at
“I met TJ several years ago and have followed the company closely since becoming aware of HTG’s technology. I believe HTG is uniquely positioned to meet the needs of next generation sequencing (NGS) based diagnostics and that the technology can be easily deployed into all labs,” said Dr. Cronin. “I’m energized to join this dynamic team and work to accelerate their pipeline of new precision diagnostic concepts and products, as well as partner with HTG’s BioPharma customers in developing best-in-class companion diagnostics.”
Dr. Cronin is the recipient of numerous academic honors, fellowships, or awards, has over two dozen issued patents, and has written pieces for over four dozen journals and books. She received her Ph.D. at the
HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our newly appointed director and her expected benefits to us and the capabilities of our technology. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, the risk that our products and services may not be adopted by biopharmaceutical companies or other customers as anticipated, or at all; our ability to manufacture our products to meet demand; the level and availability of first party payor reimbursement for our products; our ability to effectively manage our anticipated growth; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of first parties; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These and other factors are described in greater detail in our filings with the
Phone: (617) 525-7754
Source: HTG Molecular Diagnostics, Inc.